Rapilin 1mg

Rapilin 1 mg is contraindicated in patients with:

    — Type 1 diabetes

    — Diabetic ketoacidosis with or without coma

    — Co-administration of gemfibrozil

    — Known hypersensitivity to Repaglinide or its inactive ingredients

Talk to your doctor before taking Rapilin if you have the following:

    — Hepatic insufficiency; Rapilin is not recommended in patients with moderate liver disorder. Repaglinide should not be taken in case of severe liver disorder.

    — Renal impairment.

    — Under 18 or over 75 years of age, Rapilin 1 mg is not recommended.

    — About to have major surgery, or have you suffered a severe infection. At the time of severe infection, diabetic control may be lost.

Speak to your doctor if any of the above applies to you. Repaglinide may not be suitable for you. Your doctor instructs you further.

If you suffer hypoglycemia or your blood sugar gets too low: This may happen if you take too much of this medicine or exercise more than usual.

The most frequent side effect is hypoglycemia. The reaction is generally mild to moderate but may occasionally develop into unconsciousness or coma. If this occurs, medical help is needed immediately.

An allergic reaction is rare. Symptoms such as difficulty breathing, dizziness, rapid heartbeat, and sweating could be signs of an anaphylactic reaction.  

Other common side effects include stomach and diarrhoea. If you get any side effects, talk to your doctor. This includes side effects not mentioned in this information guide.  

There is no fixed dosing regimen for managing Type 2 diabetes with Rapilin. The patient's blood glucose should be monitored periodically to determine the minimum effective dose for the patient to detect primary failure Short-term administration of Rapilin may be sufficient during the transient loss of control in patients usually well-controlled on a diet. Repaglinide is usually taken within fifteen minutes of the meal, but time may vary from immediately preceding the meal to as long as thirty minutes before. The initial dose is 1 mg with each meal preprandial for patients previously treated with blood glucose-lowering drugs. Dose adjustment should be determined by blood glucose response.